OncoMatch/Clinical Trials/NCT06534762
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Is NCT06534762 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Mirabegron for nsclc.
Treatment: Mirabegron — This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research. The clinical recommend dose of this product is 50mg/day, and the dose used in this study is 100mg/day, which is larger than the clinical commonly used dose. The main adverse reactions of this product are urinary tract infection and rapid heartbeat. In the clinical study, we will focus on the urine routine and heart-related adverse events of the subjects, and deal with the adverse events in time. Subjects were given mirabeeron 100mg/day orally once a day in the morning until disease progression. When there are related or possible related side effects of the study drug mirabeeron, and according to NCI-CTCAE V 5.0, when subjects have more than or equal to grade 3 related toxicity, the administration should be delayed until grade 2 or lower to baseline, and the dose will be reduced by 50%, and subsequent dose increase is not allowed. If the pre-dose criteria are not met within 28 days, the drug will be permanently discontinued.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Colorectal Cancer
Pancreatic Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Head and Neck Squamous Cell Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic antitumor drug therapy
Exception: adjuvant/neoadjuvant therapy completed >6 months before relapse or progression
Has not received previous systemic antitumor drug therapy for metastatic/recurrent solid tumors; For subjects who have previously received neoadjuvant/adjuvant therapy, it takes more than 6 months from the last treatment to relapse or progression
Cannot have received: radiotherapy
Exception: within 4 weeks before treatment
Received the following treatment within 4 weeks before treatment: radiotherapy of tumor
Cannot have received: major surgical operation
Exception: within 4 weeks before treatment or wound not completely healed
major surgical operation or wound has not been completely healed
Cannot have received: β3 adrenoceptor agonist and corresponding clinical research drugs
Exception: within 4 weeks before treatment
β3 adrenoceptor agonist and corresponding clinical research drugs
Cannot have received: live attenuated vaccine
Exception: within 28 days prior to the first administration
received treatment with live attenuated vaccine within 28 days prior to the first administration of the study drug
Lab requirements
Blood counts
absolute value of neutrophils ≥ 1.5 × 10^9/L, platelets ≥ 100 × 10^9/L, hemoglobin concentration ≥ 9g/dL
Kidney function
serum creatinine ≤ 1.5 ×ULN, or creatinine clearance rate (CCr)≥ 60 ml/min
Liver function
bilirubin ≤ 1.5 × ULN; aspartate aminotransferase and glutamate aminotransferase ≤ 2.5 ×ULN, AST and ALT ≤ 5 ×ULN in case of liver metastasis
The function of major organs is normal, I .e. the following criteria are met (no blood transfusion, albumin, recombinant human thrombopoietin or colony stimulating factor [CSF] treatment has been received within 14 days before the first study drug administration): blood test (absolute value of neutrophils ≥ 1.5 × 10^9/L, platelets ≥ 100 × 10^9/L, hemoglobin concentration ≥ 9g/dL); Liver function test (bilirubin ≤ 1.5 × ULN; aspartate aminotransferase and glutamate aminotransferase ≤ 2.5 ×ULN, AST and ALT ≤ 5 ×ULN in case of liver metastasis); renal function (serum creatinine ≤ 1.5 ×ULN, or creatinine clearance rate (CCr)≥ 60 ml/min); coagulation function, international normalized ratio (INR)≤ 1.5 ×ULN, prothrombin time (PT) and activated partial thromboplastin time (APTT)≤ 1.5 ×ULN; thyroid function, thyroid-stimulating hormone (TSH)≤ the upper limit of normal (ULN); FT3 and FT4 levels should be examined if abnormal, and FT3 and FT4 levels are normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify